

This promotional session is sponsored by Bristol Myers Squibb.
This is intended for healthcare professionals in the UK and Republic of Ireland with an interest in oncology.

Join us!

New horizons in upper gastrointestinal (GI) cancer treatment: practical approaches to managing toxicity

Join us LIVE in Belfast!



UK Oncology Forum 2022, in person conference

Friday 17 June 2022

08:00–08:45

Belfast ICC

Bristol Myers Squibb is delighted to invite you to join us for the BMS upper GI oncology promotional symposium, live at the UK Oncology Forum 2022. The symposium will focus on the management of upper GI immunotherapy-related toxicities.

OUR EXPERT FACULTY



Professor Russell Petty

Consultant Medical Oncologist

NHS Tayside



Ms Trudy Guinan

Nurse Consultant

Clatterbridge Cancer Centre



Dr Anna Olsson-Brown

Consultant Medical Oncologist

Clatterbridge Cancer Centre

Please find the agenda below:

Time	Session title	Speaker	Type of session
08:00–08:10	Welcome and introduction: latest treatment approaches in upper GI oncology	Professor Russell Petty (Chair)	Introduction
08:10–08:25	Identifying, differentiating and managing IO and CT-related toxicity	Trudy Guinan	Presentation from an expert speaker
08:25–08:40	Supporting your MDT and beyond to deliver best practice in toxicity management	Dr Anna Olsson-Brown	Presentation from an expert speaker
08:40–08:45	Summary and close	Professor Russell Petty (Chair)	Summary

GI: gastrointestinal; IO: immunotherapy; CT: chemotherapy; MDT: multi-disciplinary team

[Click here to submit your questions to the faculty](#)

OPDIVO® (nivolumab) is indicated: In combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a CPS ≥ 5 .¹

¹.OPDIVO. Summary of Product Characteristics.
Available at: <https://www.medicines.org.uk/emc/medicine/30476> (accessed May 2022).

[OPDIVO® \(nivolumab\) prescribing information can be found here](#)

Adverse events should be reported. Reporting forms and information can be found at:
UK - www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store; Ireland - via HPRA Pharmacovigilance at www.hpra.ie
Adverse events should also be reported to Bristol Myers Squibb via medical.information@bms.com or 0800 731 1736 (UK); 1 800 749 749 (Ireland).